Navigation Links
CHPA Statement on PSE Economic Study By AEI Fellow Alex Brill

WASHINGTON, March 8, 2013 /PRNewswire-USNewswire/ -- The Consumer Healthcare Products Association (CHPA) released a statement today on a recent study conducted by American Enterprise Institute fellow Alex Brill and supported by a grant from CHPA. Brill previously served as the chief economist for the U.S. House Committee on Ways and Means from 2002-2007.  His economic policy consulting firm, Matrix Global Advisors, published the study March 4.

With consideration to both the economic costs on the healthcare system and consumers, the study examines the unintended impacts of a prescription-only policy for cold and allergy medicines containing pseudoephedrine (PSE) and finds:

  • Extra doctor visits, contributing $59 million in additional costs to the government, consumers, and private insurance companies in the first year following the policy's implementation;
  • More absenteeism and lost work productivity, when the common cold already costs this nation an estimated $25 billion annually in lost productivity;
  • Higher prices for PSE medicines due to the overall cost difference between a prescription-only product and an over-the-counter one;
  • Increased health insurance premiums due to additional doctor visits and higher PSE drug costs;
  • An estimated loss of $219.2 million in state tax revenues over ten years.

"There is no question that certain states struggle with domestic methamphetamine production," said Alex Brill , chief executive officer of Matrix Global Advisors. "However, my analysis left me convinced that the serious economic and social consequences of a prescription requirement, coupled with the dominance of Mexican drug cartels in the American meth market, should give lawmakers pause before pursuing such a policy."

"Recent consumer surveys clearly demonstrate that law-abiding citizens oppose legislation that would force them to consult with a doctor in order to buy the cold and allergy medicines of their choice," said David Spangler , senior vice president, policy and general counsel at CHPA. "This study provides us with a better understanding of the consumer burden by quantifying the economic impact a prescription requirement would have—most importantly  on consumers— but also on businesses and state governments as well."

Editor's note: To access Brill's complete study, visit

CHPA is the 132-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and dietary supplements.

SOURCE Consumer Healthcare Products Association
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
2. CHPA Statement on Statewide Indiana Consumer Poll
3. Sonitus Medical Announces Affirmative Update Regarding Bone Conduction Oral Appliances in American Academy of Otolaryngology-Head and Neck Surgery Policy Statement on Implantable Hearing Devices
4. Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients
5. Statement from Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, on the Front Page New York Times Story Regarding the Pre-emptive Strikes of Amgen/Genentech to Restrict Access to Affordable and Safe Biosimilars
6. Emmaus Life Sciences Issues Statement in Response to Announcement by AFH Holding & Advisory
7. Hill-Rom Reports Fiscal First Quarter Results; Updates 2013 Financial Outlook For R&D Tax Credit Reinstatement
8. CVS Caremark Statement and Response to CMS Action
9. World Renowned Scientist, Dr. Rongxiang Xu Speaks Out About Nobel Assembly Statement Claiming They Have Not Heard Of Him
11. PCMA Statement on Essential Health Benefits Proposed Rule
Post Your Comments:
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
Breaking Medicine News(10 mins):